Skip to main content

6 February 2013

Smiths Medical, a division of global technology business Smiths Group, has received a key clearance from the US Food and Drug Administration (FDA) to launch an advanced version of its portable infusion system designed specifically for home care.

The new CADD®-Solis VIP, which can now be marketed in the US, features advanced medication safety software that alerts operators or interrupts the infusion process when a pump setting is programmed outside preconfigured limits.

Srini Seshadri, President of Smiths Medical, said: “The CADD®-Solis VIP provides enhanced safety features and convenience for healthcare providers who want to provide optimal care for their infusion patients in the home. The FDA 510 (k) clearance allows it to be sold in our biggest single market by far.”

The CADD®-Solis VIP is used to administer pain relief medications, including narcotics, to post-surgery, trauma, cancer and labour patients. The patented software built into the system is also designed to recognise prescription errors, dose misinterpretations, and keypad programming mistakes.  It is currently available in France, Germany, Switzerland, the Netherlands, Canada, Australia, the UK, and the Middle East.

Related articles

Earth View

Smiths Group plc – Q3 Trading Update

Find out more Call to action arrow icon

Smiths Group appoints Kini Pathmanathan as Head of Smiths Excellence & Sustainability

Find out more Call to action arrow icon
Belfast City Airport

Smiths Detection to supply Belfast International Airport with 3D X-ray scanners

Find out more Call to action arrow icon